ARCT

SEC source: 0001193805-26-000828 · e665583_4-farrell.xml · derivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000827 · e665582_4-barlow.xml · derivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000829 · e665584_4-holmes.xml · derivative · entry 1

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000824 · e665579_4-marquet.xml · derivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000825 · e66580_4-slaoui.xml · derivative · entry 1

Slaoui Moncef · CIK 0001712369 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000826 · e665581_4-markels.xml · derivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000823 · e665578_4-jing.xml · derivative · entry 1

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-05

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-26-000578 · e665445_4-mulroy.xml · derivative · entry 1

MULROY DENNIS · CIK 0001276840 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-05-01

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-25-001765 · e665059_4-payne.xml · derivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2035-12-17

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-25-001766 · e665060_4-chivukula.xml · derivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,000

Underlying: Common Stock · 54,000 shares

Expires 2035-12-17

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-25-001767 · e665069_4-roberts.xml · derivative · entry 1

Roberts Joseph · CIK 0002101782 · Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-12-17

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-25-001764 · e665058_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,000

Underlying: Common Stock · 54,000 shares

Expires 2035-12-17

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-25-001212 · e664791_4-sassine.xml · nonDerivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,764

F1 · kind: The purchase reported on this Form 4 was effected by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2025.

SEC source: 0001193805-25-001215 · e664797_4a-sassine.xml · nonDerivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,764

F1 · kind: The purchase reported on this Form 4 was effected by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2025.

SEC source: 0001193805-25-000873 · e664619_4-barlow.xml · derivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-25-000878 · e664624_4-farrell.xml · derivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-25-000872 · e664618_4-holmes.xml · derivative · entry 1

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-25-000876 · e664622_4-marquet.xml · derivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-25-000877 · e664623_4-slaoui.xml · derivative · entry 1

Slaoui Moncef · CIK 0001712369 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-25-000875 · e664621_4-markels.xml · derivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-25-000874 · e664620_4-jing.xml · derivative · entry 1

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-09

F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-001490 · e664083_4-sassine.xml · derivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-12-16

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-24-001492 · e664085_4-payne.xml · derivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,000

Underlying: Common Stock · 196,000 shares

Expires 2034-12-16

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-24-001491 · e664084_4-chivukula.xml · derivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-12-16

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-24-001493 · e664086_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-12-16

F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-24-001248 · e663956_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 435,334

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 12,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 15, 2024, with sale prices ranging from $20.03 to $21.12 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-24-000836 · e663735_4-jing.xml · derivative · entry 2

Slaoui Moncef · CIK 0001712369 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,794

Underlying: Common Stock · 14,794 shares

Expires 2034-06-19

F2 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board.

SEC source: 0001193805-24-000836 · e663735_4-jing.xml · derivative · entry 1

Slaoui Moncef · CIK 0001712369 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors.

SEC source: 0001193805-24-000824 · e663725_4-farrell.xml · derivative · entry 4

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-14

F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-000824 · e663725_4-farrell.xml · derivative · entry 3

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000824 · e663725_4-farrell.xml · nonDerivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000825 · e663726_4-barlow.xml · derivative · entry 3

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-14

F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-000825 · e663726_4-barlow.xml · derivative · entry 2

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000825 · e663726_4-barlow.xml · nonDerivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000828 · e663729_4-holmes.xml · derivative · entry 3

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-14

F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-000828 · e663729_4-holmes.xml · derivative · entry 2

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000828 · e663729_4-holmes.xml · nonDerivative · entry 1

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000826 · e663727_4-marquet.xml · derivative · entry 4

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-14

F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-000826 · e663727_4-marquet.xml · derivative · entry 3

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000826 · e663727_4-marquet.xml · nonDerivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000829 · e663730_4-jing.xml · derivative · entry 3

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-14

F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-000829 · e663730_4-jing.xml · derivative · entry 2

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000829 · e663730_4-jing.xml · nonDerivative · entry 1

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000827 · e663728_4-markels.xml · derivative · entry 3

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-14

F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

SEC source: 0001193805-24-000827 · e663728_4-markels.xml · derivative · entry 2

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000827 · e663728_4-markels.xml · nonDerivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

SEC source: 0001193805-24-000801 · e663716_4-sassine.xml · nonDerivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,526

F1 · kind: The sales reported on this Form 4 were effected in open market transactions by the Reporting Person.

F2 · price: Reflects the weighted average price of 50,000 shares of common stock of Arcturus Therapeutics Holdings Inc. (the "Issuer") sold by the Reporting Person in multiple transactions on June 12, 2024, with sales prices ranging from $31.52 to $33.54 per share. The Reporting Person undertakes to provide, upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-24-000768 · e663692_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 447,334

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the price of 114 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person on June 5, 2024. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-24-000746 · e663681_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 447,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 26,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on June 3, 2024, with sale prices ranging from $40.00 to $40.325 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-24-000452 · e663461_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 473,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 17,435 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 25, 2024, with sale prices ranging from $35.00 to $35.045 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.